Biogen News and Research

RSS
Global market for oncology drugs is forecast to reach $80 billion by 2050

Global market for oncology drugs is forecast to reach $80 billion by 2050

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec's statement on FDA approval of AMPYRA

TTI enters into definitive license agreement with Biogen Idec

TTI enters into definitive license agreement with Biogen Idec

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

REC releases social responsibility report on top global pharmaceutical companies

REC releases social responsibility report on top global pharmaceutical companies

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec increases its offer to $17.50 for purchase of Facet Biotech shares

Biogen Idec increases its offer to $17.50 for purchase of Facet Biotech shares

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

Article on TYSABRI for treating patients with multiple sclerosis published

Article on TYSABRI for treating patients with multiple sclerosis published

Receptos raises $25 million through Series A financing

Receptos raises $25 million through Series A financing

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Caliper Life Sciences presents the benefits of its LabChip GX platform

Caliper Life Sciences presents the benefits of its LabChip GX platform